Last updated: November 2, 2026
KINLYTIC, the U.S. brand for urokinase, is an established thrombolytic biologic with limited current commercial visibility. Its market position deteriorated after competition from alteplase and other fibrinolytics, manufacturing disruptions, restricted hospital use, and the absence of a large promotional franchise. Public filings do not report a reliable standalone revenue series for KINLYTIC. The product’s commercial value is therefore driven more by supply continuity, hospital formulary access, and manufacturing capability than by patent exclusivity.
What is KINLYTIC and what clinical markets does it serve?
KINLYTIC is a purified human urokinase preparation that converts plasminogen to plasmin, promoting fibrin degradation. Its FDA-approved use is thrombolytic treatment of massive pulmonary embolism, including cases involving hemodynamic instability, when the benefits of treatment outweigh bleeding risks.[1]
Urokinase has also been used in hospital practice for catheter-directed thrombolysis and vascular-device clearance. Those uses should not be treated as equivalent to the current FDA-approved KINLYTIC label unless supported by the applicable product labeling and institutional protocols.
KINLYTIC product profile
| Attribute |
KINLYTIC |
| Active ingredient |
Urokinase |
| Drug class |
Fibrinolytic thrombolytic |
| Molecular type |
Human serine protease biologic |
| Primary approved use |
Pulmonary embolism |
| Administration |
Intravenous infusion |
| Primary customers |
Hospitals, intensive-care units, emergency departments |
| Principal competitors |
Alteplase, tenecteplase, streptokinase, catheter-directed thrombolytic products |
| Commercial characteristic |
Low-volume, acute-care, supply-sensitive product |
| Regulatory status |
FDA-approved historical urokinase product; current commercial availability requires verification against FDA and manufacturer records |
The clinical market is concentrated. Urokinase is not a chronic-use medicine and does not generate recurring retail prescriptions. Purchases are episodic and tied to acute thromboembolic events, hospital protocols, inventory decisions, and emergency preparedness.
How has the KINLYTIC market evolved?
KINLYTIC inherited a mature urokinase market rather than creating a new therapeutic category. Urokinase was used clinically in the United States before the modern dominance of recombinant tissue plasminogen activators. Alteplase gained share because of broad clinical familiarity, extensive trial support, established hospital protocols, and commercial investment by Genentech and its successors.
The market has passed through four identifiable phases:
| Period |
Market condition |
Commercial effect |
| Pre-2000 |
Urokinase established in thrombolysis |
Stable but specialized demand |
| 2000-2008 |
Product reauthorization and supply changes |
Market disruption and uncertain availability |
| 2008-2015 |
Competition from alteplase and newer thrombolytics |
Lower strategic importance for urokinase |
| 2016-present |
Mature hospital market and generic or alternative thrombolytic pressure |
Price and supply become more important than brand differentiation |
KINLYTIC demand is structurally inelastic during a shortage but weak under normal supply conditions. Hospitals may pay a premium for reliable access because thrombolytics are emergency drugs, yet procurement departments can switch among clinically acceptable agents when protocols, dosing, and reimbursement permit.
What is the financial trajectory of KINLYTIC?
Publicly available company disclosures do not establish a dependable, standalone KINLYTIC revenue history. The product has generally been embedded within broader corporate reporting, licensing arrangements, or pharmaceutical segments rather than reported as a separately audited operating unit.
The financial trajectory can therefore be assessed through commercial indicators rather than precise annual sales:
- Urokinase moved from an established thrombolytic product to a niche hospital medicine.
- Revenue potential declined as alteplase became the dominant branded fibrinolytic in many institutions.
- Supply interruptions increased the value of manufacturing capacity but did not create durable brand growth.
- The product’s economics became dependent on contract pricing, hospital tenders, and production continuity.
- The absence of a broad outpatient market limited volume expansion.
Revenue exposure and market size
KINLYTIC does not have the revenue profile of a mass-market biologic. Its exposure is concentrated in:
- Acute pulmonary embolism treatment.
- Hospitals that maintain urokinase in thrombolytic protocols.
- Specialty vascular and interventional settings.
- Periods when competing thrombolytics are unavailable or constrained.
- Markets where urokinase pricing is favorable relative to alteplase.
Revenue concentration creates volatility. A manufacturer can experience higher demand during a competitor shortage without gaining permanent market share. Conversely, a manufacturing interruption can reduce sales rapidly because hospitals often shift to substitute thrombolytics.
No reliable public source supports a current, brand-specific KINLYTIC revenue estimate. Any precise figure would require confidential manufacturer data, prescription audits, hospital purchasing data, or transaction-level market research.
When does KINLYTIC lose exclusivity?
KINLYTIC is an old biologic product, and its principal commercial protection is not a current, high-value composition-of-matter patent estate. Urokinase itself was described in patents and scientific literature decades before the current biologics framework matured.
Patent and regulatory exclusivity
| Protection category |
KINLYTIC position |
| Composition patent |
No commercially meaningful current protection identified for the urokinase molecule |
| New chemical entity exclusivity |
Not applicable to this old biologic product |
| Orphan-drug exclusivity |
Not identified for KINLYTIC’s principal pulmonary embolism indication |
| Formulation exclusivity |
No significant current exclusivity identified |
| Method-of-use exclusivity |
No current blocking exclusivity identified that would support a durable U.S. monopoly |
| Pediatric exclusivity |
No material current protection identified |
| Regulatory market protection |
Historical approval protection has expired |
| Biosimilar reference-product exclusivity |
Any applicable period would have expired given the age of the product |
The relevant commercial question is not when a single patent expires. It is whether another manufacturer can meet regulatory, manufacturing, quality, and supply requirements for a human-derived thrombolytic product.
What patents protect KINLYTIC?
The current KINLYTIC opportunity is unlikely to be protected by a live patent covering the basic urokinase active ingredient. Potential historical patent categories include:
- Methods for isolating or purifying urokinase.
- Cell-culture or biological production processes.
- Stabilized urokinase formulations.
- Dosage and infusion protocols.
- Manufacturing controls for activity and purity.
- Container-closure and lyophilization systems.
These categories do not automatically create an enforceable commercial barrier. Patent term, claim scope, prosecution history, ownership, maintenance fees, and freedom-to-operate analysis must be assessed for each jurisdiction.
Manufacturing IP barriers
The strongest practical barrier is likely manufacturing know-how rather than patent term. Relevant controls include:
- Source-material qualification.
- Viral and adventitious-agent control.
- Protease activity and potency testing.
- Batch consistency.
- Protein aggregation control.
- Sterility and endotoxin management.
- Lyophilization and reconstitution performance.
- Stability dating.
- Validation of purification and fill-finish operations.
For an old biologic, these manufacturing requirements can deter entry even when the core molecule is off-patent. A prospective competitor must demonstrate consistent biological activity and acceptable comparability through the applicable FDA pathway.
What is the FDA regulatory status of KINLYTIC?
Urokinase predates the current commercial environment for biosimilars and modern biologics. FDA approval history includes legacy urokinase products and later product-specific regulatory actions. FDA labeling identifies the thrombolytic indication, dosing requirements, contraindications, warnings, and bleeding risks.[1]
The regulatory record must be reviewed directly through Drugs@FDA, the product label, FDA biologics records, and the Orange Book where applicable. Older biologic products may not map cleanly onto the conventional small-molecule NDA and ANDA framework.
Does KINLYTIC have an Orange Book listing?
KINLYTIC’s Orange Book position should not be assumed to mirror that of a modern small-molecule drug. The Orange Book primarily supports approved drug products and patent/exclusivity information for products regulated under the applicable NDA framework.[2]
For KINLYTIC, the commercial analysis should distinguish:
- FDA approval status.
- Product marketing status.
- Patent-listing status.
- Biologic-license status.
- Availability of an abbreviated pathway for a competing urokinase product.
- Any state or federal substitution rules.
An absence of an active Orange Book patent listing would not eliminate regulatory or manufacturing barriers.
Are there Paragraph IV challenges to KINLYTIC?
No material, publicly prominent Paragraph IV litigation campaign is associated with KINLYTIC in the way seen for major small-molecule products. That result is consistent with the product’s age, biologic history, limited revenue opportunity, and lack of a valuable patent thicket.
Paragraph IV risk is also structurally less central where the reference product is regulated as a biologic rather than through a conventional ANDA pathway. A competing developer may need to pursue a biologics pathway, a product-specific approval route, or another regulatory mechanism rather than relying on a standard ANDA certification.
Generic and follow-on entry risk
The entry risk is real but not equivalent to ordinary generic substitution. A competing manufacturer would face:
- Product characterization requirements.
- Clinical and analytical comparability questions.
- Process validation.
- Immunogenicity and safety assessment.
- Facility inspection.
- Reliable supply commitments.
- Hospital acceptance and formulary conversion.
A follow-on urokinase product could enter without infringing a live composition patent, but commercial success would depend on manufacturing economics and regulatory execution.
Which companies challenge KINLYTIC in the thrombolytic market?
The main competitive threat comes from alternative thrombolytics rather than direct urokinase copies.
| Competitor |
Company association |
Competitive basis |
| Activase, alteplase |
Genentech/Roche |
Strong clinical adoption, broad thrombolytic use, established protocols |
| TNKase, tenecteplase |
Genentech/Roche |
Bolus administration and growing use in selected acute-care settings |
| Streptase, streptokinase |
Multiple regional suppliers |
Lower-cost fibrinolytic option in some markets |
| Catheter-directed thrombolytic products |
Multiple manufacturers |
Procedural use in vascular and interventional settings |
| Follow-on urokinase products |
Potential regional manufacturers |
Price, availability, and supply diversification |
Tenecteplase has increased competitive pressure where hospitals favor simpler administration. Alteplase remains a major comparator because of its broad clinical familiarity and extensive evidence base.
How does KINLYTIC compare with alteplase and tenecteplase?
| Factor |
KINLYTIC |
Alteplase |
Tenecteplase |
| Active ingredient |
Urokinase |
Recombinant tPA |
Modified recombinant tPA |
| Administration complexity |
Infusion-based |
Infusion-based |
Bolus-based in several settings |
| Brand strength |
Limited |
High |
High and expanding |
| Hospital familiarity |
Specialized |
Broad |
Increasing |
| Patent value |
Minimal current value |
Historically significant |
Historically significant |
| Commercial demand |
Niche |
Broad acute-care demand |
Growing acute-care demand |
| Main advantage |
Established fibrinolytic mechanism |
Evidence and market penetration |
Simplified administration |
| Main weakness |
Limited differentiation |
Cost and bleeding risk |
Indication-specific adoption and pricing |
KINLYTIC’s clinical differentiation is insufficient to support premium brand economics without a supply advantage, price advantage, or a defined institutional niche.
What litigation and settlement agreements affect KINLYTIC?
No major current patent litigation or public Paragraph IV settlement is widely associated with KINLYTIC. Historical commercial disputes may have involved manufacturing rights, product supply, licensing, or regulatory ownership, but those matters do not appear to have created a current patent-driven exclusion period comparable to major branded medicines.
The absence of visible litigation reduces legal uncertainty but also indicates that the product lacks a valuable active patent position. Any transaction involving KINLYTIC should prioritize regulatory ownership, manufacturing rights, supply agreements, indemnities, product liability allocation, and facility qualification.
What licensing deals support KINLYTIC?
KINLYTIC has been associated with commercial arrangements involving product rights, manufacturing, and distribution rather than a high-value discovery license. Public disclosures have not established a current, transparent royalty stream or a major strategic alliance that materially changes the product’s market outlook.
For diligence purposes, the highest-value contractual issues are:
- Territory-specific commercialization rights.
- FDA application ownership and transfer rights.
- Manufacturing exclusivity.
- Minimum purchase obligations.
- Shortage allocation rights.
- Change-of-control provisions.
- Product liability insurance.
- Technology-transfer obligations.
- Rights to regulatory submissions and manufacturing records.
What generic launch scenarios exist for KINLYTIC?
Scenario 1: No direct entrant
KINLYTIC remains a limited-volume product supported by specialized demand. Revenue stays dependent on supply continuity and institutional contracts.
Scenario 2: Regional follow-on urokinase entrant
A lower-cost manufacturer enters selected markets. KINLYTIC loses price-sensitive hospital accounts but retains customers that value established supply and regulatory history.
Scenario 3: Supply-driven substitution
A KINLYTIC manufacturing interruption shifts demand to alteplase, tenecteplase, or streptokinase. Recovery may not restore the prior customer base because hospitals update protocols and contracts during the shortage.
Scenario 4: Procedure-driven decline
Improved adoption of mechanical thrombectomy, catheter-directed intervention, or newer thrombolytic protocols reduces demand for systemic urokinase in selected indications.
How strong is the KINLYTIC patent estate?
The patent estate is weak from a current commercial-exclusivity perspective. The molecule is old, the major patent categories are likely expired or nonblocking, and no prominent active patent litigation defines the market. The stronger barriers are regulatory compliance, biological manufacturing, product quality, and hospital procurement.
| Risk factor |
Assessment |
| Patent expiration risk |
Low, because meaningful basic protection is not apparent |
| Follow-on product risk |
Moderate |
| Manufacturing interruption risk |
High |
| Substitution risk |
High |
| Regulatory reapproval risk |
Moderate to high for a new entrant |
| Pricing power |
Limited to moderate during shortages |
| Long-term growth potential |
Low without a new indication or delivery advantage |
Key Takeaways
- KINLYTIC is a mature urokinase thrombolytic with a niche hospital market.
- Its main commercial competitors are alteplase and tenecteplase, not only direct urokinase products.
- Public filings do not provide a reliable standalone KINLYTIC revenue history.
- No material current patent monopoly or prominent Paragraph IV litigation campaign defines the product.
- Manufacturing quality, supply reliability, and FDA compliance are more important than patent duration.
- Generic or follow-on entry is possible but would face substantial biologic manufacturing and regulatory requirements.
- Revenue exposure is limited, episodic, and concentrated in acute-care institutions.
- The most credible downside is substitution after supply disruption or protocol migration to newer thrombolytics.
FAQs
Is KINLYTIC still commercially available in the United States?
Commercial availability has varied by period and supplier. FDA approval history and current manufacturer distribution records must be checked because approval does not guarantee active commercial supply.
Is urokinase a biosimilar to alteplase?
No. Urokinase and alteplase are different thrombolytic proteins with different biological origins and molecular structures. A urokinase follow-on product would be compared with urokinase, not treated as an alteplase biosimilar.
Does KINLYTIC have meaningful patent protection in Europe?
The basic urokinase molecule is too old for ordinary current composition-patent protection. European commercial barriers would more likely involve national regulatory requirements, manufacturing rights, formulation claims, and supply arrangements.
Can hospitals automatically substitute a generic urokinase product for KINLYTIC?
Not necessarily. Substitution depends on the product’s regulatory classification, approval status, institutional formulary rules, pharmacy policy, and applicable national or state law.
What would increase KINLYTIC’s commercial value?
A durable supply advantage, a lower-cost validated manufacturing process, a new approved indication, a differentiated delivery format, or a strategic shortage position could increase value. Patent recovery alone is unlikely to produce a major commercial expansion.
References
-
U.S. Food and Drug Administration. (2009). KINLYTIC (urokinase) prescribing information. FDA/DailyMed labeling record.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
U.S. Food and Drug Administration. (2024). Product-specific guidance and regulatory information for biological products. FDA.
